Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes kidney drug shows promise in slowing damage

NCT ID NCT03436693

Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether canagliflozin, a diabetes drug, can slow kidney decline in 308 Japanese patients with diabetic nephropathy. Participants took either the drug or a placebo daily for about two years. The main goal was to see if fewer people on the drug had a 30% drop in kidney function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
canagliflozin
What this could lead to
If successful, this could provide a new option to slow kidney damage in people with diabetes-related kidney disease.
What could go wrong
This is a completed Phase 3 trial in Japanese patients only, so results may not apply to other populations. The drug may not significantly slow kidney decline compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

308 people

The number who actually took part.

Started

Feb 2018

Finished

Jan 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

30 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Additional criteria check may apply for qualification: * Glycated hemoglobin(HbA1c) of ≥6.5% and ≤12.0% * eGFR of ≥30 mL/min/1.73m2 and \<90 mL/min/1.73m2 * The median UACR of the first morning void urine samples is ≥300 mg/g Cr and ≤5000 mg/g Cr * Patients who are taking on angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) * Patients who are under dietary management and taking therapeutic exercise for diabetes Exclusion Criteria: Additional criteria check may apply for qualification: * Type I diabetes, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes * A diagnosis of non-diabetic renal disease * Hereditary glucose-galactose malabsorption or primary renal glucosuria * Class IV heart failure symptoms according to New York Heart Association (NYHA) functional classification * Severe hepatic disorder or severe renal disorder * Blood potassium level \>5.5 mmoL/L * Stable blood pressure (diastolic blood pressure (DBP) ≥100mmHg or systolic blood pressure (SBP) ≥180mmHg)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic nephropathy

Contacts and locations

Locations

  • Research site

    Aichi, Japan

  • Research site

    Chiba, Japan

  • Research site

    Fukuoka, Japan

  • Research site

    Fukushima, Japan

  • Research site

    Gunma, Japan

  • Research site

    Hiroshima, Japan

  • Research site

    Hokkaido, Japan

  • Research site

    Hyōgo, Japan

  • Research site

    Ibaraki, Japan

  • Research site

    Kagawa, Japan

  • Research site

    Kagoshima, Japan

  • Research site

    Kanagawa, Japan

  • Research site

    Kumamoto, Japan

  • Research site

    Mie, Japan

  • Research site

    Nagano, Japan

  • Research site

    Nagasaki, Japan

  • Research site

    Okinawa, Japan

  • Research site

    Osaka, Japan

  • Research site

    Ōita, Japan

  • Research site

    Saitama, Japan

  • Research site

    Shizuoka, Japan

  • Research site

    Tochigi, Japan

  • Research site

    Tokyo, Japan

  • Research site

    Wakayama, Japan

  • Research site

    Yamagata, Japan

  • Research site

    Yamaguchi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.